Top AI Companies in Dallas, TX (105)

Strong Revenue Growth: Sales and revenues have set new records and accelerated in early 2026, with double-digit year-over-year gains and multiple quarters at all-time highs. A record and growing backlog is described as supporting continued momentum.

Strong Market Position & Advantage: The company is repeatedly identified as the global leader in construction and mining equipment, reinforced by independent rankings and its extensive dealer network. Scale, connected assets, and autonomous deployments are presented as competitive advantages.

Profitability: Operating margin and profit per share improved markedly in 2026, with quarterly margins rebounding versus the prior year. Management also raised guidance alongside stronger segment performance, pointing to recovering earnings power.

Resilient & Sustainable Growth: Revenue has increased year over year to a new high, with all three major service lines posting gains despite a slower pace. Growth remains uneven by region, but the overall trajectory is upward over the last several fiscal years.

Future-Ready Strategy: Multi‑billion‑dollar investments in technology—especially nearly $1.5B in AI—along with acquisitions and scaling managed services indicate a deliberate pivot to future growth levers. Leadership attention to next‑generation audit and AI‑enabled capabilities underscores preparation for emerging demand.

Strong Market Position & Advantage: The organization is characterized as a leading global professional‑services network with broad scale across assurance, advisory, and tax and repeated external recognitions in select consulting categories. Reach across major multinational clients supports durable competitive positioning.

Strong Revenue Growth: ARR is reported as more than tripled in 2025, with annual recurring subscription and service revenue increasing by over 220%. Growth is attributed to new and expanding relationships with private equity sponsors and their portfolio companies.

Market Expansion: Office openings and relocations across Chicago, Dallas, New York, and Toronto, plus expanded sponsor footprint and portfolio reach, indicate widening geographic and commercial coverage. The company cites doubling sponsor partnerships and reach into a network representing about $400B AUM.

Strong Hiring & Retention: Headcount is estimated to have risen sharply over 2023–2026, and multiple executive appointments (e.g., EVPs for Finance & Corporate Development and for Technology & Operations) were made to support scaling. Added locations and planned team growth in hubs like Chicago and New York further signal ongoing talent expansion.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Strong Revenue Growth: Revenue appears to be increasing over time, with evidence of substantial growth in 2022 and continued year-over-year expansion into early 2023, even as the pace moderates. Feedback suggests the business is still scaling toward a larger revenue base while transitioning to a mature growth profile.

Profitability: Independent credit commentary highlights improved profitability and a deliberate shift toward a profit-focused operating model. Feedback suggests efficiency gains and margin improvement are becoming central to the company’s stability and growth trajectory.

Innovation-Driven Growth: Ongoing AI platform investment, rising adoption of AI capabilities, and product expansion including acquisitions are cited as current growth engines. Feedback suggests these initiatives are supporting continued operational and market expansion.

Strong Revenue Growth: Revenue increased year over year in the latest quarters, with momentum accelerating into Q2 2026. Monetization per user improved, helping top-line growth outpace audience expansion.

Healthy Cash Flow: Adjusted EBITDA and free cash flow rose sharply, and the company generated positive free cash flow in the latest quarter. These gains indicate stronger operating leverage versus a year earlier.

Diversified Revenue Streams: Subscription and other direct-revenue products such as Snapchat+ expanded rapidly alongside core advertising. “Other revenue” grew significantly and the direct-revenue run rate scaled materially.

Strong Revenue Growth: Reported results indicate rapid top-line expansion through 2025 with continued momentum into early 2026 and reaffirmed guidance toward the billion‑dollar range. Feedback suggests this trajectory is anchored by rising therapy‑selection volumes and improving margins with positive adjusted EBITDA and cash generation noted.

Strategic Partnerships: A large, academically anchored Precision Oncology Alliance, deeper Epic EHR integration, and multiple biopharma collaborations provide distribution leverage and evidence‑generation capacity. These relationships appear to support broader adoption, data scale, and pipeline progression.

Innovation-Driven Growth: Routine WES/WTS and launches such as MI Cancer Seek (FDA‑approved WES/WTS‑based CDx), Caris Assure, and ChromoSeq, with Caris Detect planned, indicate a robust product and AI/ML innovation engine. This multi‑omic breadth differentiates clinical offerings and strengthens the company’s data and modeling assets.

Strong Revenue Growth: Trade coverage indicates sustained double‑digit growth across 2024–2025 and substantial managed media spend. Recent high‑profile AOR wins and early‑2026 new‑business momentum reinforce the trajectory.

Strong Market Position & Advantage: Industry honors (e.g., Independent Agency of the Year) and a blue‑chip client roster signal competitive strength among independent, tech‑forward media/marketing agencies. Consistent recognition across multiple years points to durable standing rather than a one‑off result.

Market Expansion: New offices in Mexico City and Toronto, alongside acquisitions in retail media and influencer marketing, extend geographic reach and capabilities. Prior deals in CTV/OTT and the U.K./EU further support scaled indie positioning.

Diversified Revenue Streams: Service mix content indicates the company blends IT staffing and contingent workforce with AI/ML, automation, data, mobile, and cloud services. Feedback suggests this one‑vendor model appeals to buyers seeking both talent augmentation and project delivery.

Market Expansion: Company materials and third‑party profiles point to operations across North America, Europe, Asia, and Australia with roughly 20 locations and a global delivery footprint. Public activity such as ongoing LinkedIn content and open roles indicates continued pursuit of new markets and accounts.

Future-Ready Strategy: Positioning emphasizes AI/automation offerings, industry‑packaged solutions in areas like healthcare, manufacturing, and pharma, and agentic‑AI delivery. Compliance claims such as SOC 2 Type II and ISO 27001, alongside HIPAA‑aware workflows, support readiness for regulated use cases.

Strong Market Position & Advantage: Repeated UCaaS Leader placements by Gartner through 2024/2025 and third-party data citing #1 UCaaS share by revenue and seats underscore a durable position in core UCaaS. High scores in Gartner Critical Capabilities and continued presence on enterprise short lists reinforce perceived competitive strength.

Healthy Cash Flow: Free cash flow increased year over year in early 2026 with guidance raised to $615M–$625M, alongside GAAP operating margin expansion. Dividend initiation and a subsequent ~67% hike, plus repaid 2026 notes and no maturities until 2030, signal confidence in ongoing cash generation.

Strategic Partnerships: Exclusive UCaaS partnership with Mitel and the ongoing Avaya relationship expand distribution and migrations from on-premises systems. An expanded two-way partnership with NICE in 2026 for integrated UCaaS/CCaaS further amplifies ecosystem reach.

Strong Revenue Growth: Comparable revenue increased in FY2025 and the company reports a positive start to FY2026 on a comparable basis while reaffirming its full-year comparable growth guidance.

Profitability: Adjusted EBIT margin rose in FY2025, and free cash flow improved alongside a higher proposed dividend, indicating strengthened operating performance and shareholder returns.

Strong Market Position & Advantage: The company is positioned as a leader in medical technology, with noted dominance in diagnostic imaging and continued momentum in Imaging and Precision Therapy helping sustain growth despite pressures elsewhere.